De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
Table 2
Antibody characteristics in 39 de novo donor specific HLA antibody (dnDSA) positive patients.
Variables
All patients with dnDSAs ()
Patients with dnDSAs occurring within year 1 ()
Patients with dnDSAs occurring beyond year 1 ()
value
dnDSA specificities,
1.97 ± 1.29
1.87 ± 1.25
2.04 ± 1.33
0.68
dnDSAs
35 (90%)
13 (87%)
22 (92%)
0.63
HLA class I dnDSAs
8 (21%)
2 (13%)
6 (25%)
0.45
HLA class II dnDSAs
18 (46%)
8 (53%)
10 (42%)
0.52
HLA class I and II dnDSAs
13 (33%)
5 (33%)
8 (33%)
1.00
HLA-A dnDSAs
16 (41%)
5 (33%)
11 (61%)
0.51
HLA-B dnDSAs
12 (31%)
3 (20%)
9 (37%)
0.30
HLA-C dnDSAs
7 (18%)
3 (20%)
4 (17%)
1.00
HLA-DR dnDSAs
6 (15%)
3 (20%)
3 (12%)
0.66
HLA-DQ dnDSAs
28 (72%)
11 (73%)
17 (71%)
1.00
HLA-DP dnDSAs
1 (3%)
0
1 (4%)
1.00
Immunodominant dnDSAs
9501 ± 7198
10483 ± 7020
8888 ± 7387
0.51
12043 ± 7842
12061 ± 6683
12031 ± 8626
0.99
C1q positivityof dnDSAs
At dnDSA onset
25 (64%)
12 (80%)
13 (54%)
0.17
At biopsy or MFI peak
29 (74%)
12 (80%)
17 (71%)
0.71
C3d positivityof dnDSAs
At dnDSA onset
9 (23%)
3 (20%)
6 (25%)
1.00
At biopsy or MFI peak
16 (41%)
6 (40%)
10 (42%)
1.00
Percentages are calculated on the total number of patients from each group indicated at the top of the respective columns. All data are reported as absolute numbers, unless otherwise specified; data reported as mean ± sd. DSA persistence was defined as positivity of the immunodominant DSA in all analyzed samples after first positivity. MFI: mean fluorescence intensity.
